Search Results - "Naik, Snehal U."

Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo by NAIK, Snehal U, XUN WANG, DA SILVA, Jaqueline S, JAYE, Michael, MACPHEE, Colin H, REILLY, Muredach P, BILLHEIMER, Jeffrey T, ROTHBLAT, George H, RADER, Daniel J

“…Liver X receptors (LXRs) are ligand-activated transcription factors involved in the control of lipid metabolism and inflammation. Synthetic LXR agonists have…”
Get full text

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis by Sandborn, William J., Peyrin-Biroulet, Laurent, Zhang, Jinkun, Chiorean, Michael, Vermeire, Séverine, Lee, Scott D., Kühbacher, Tanja, Yacyshyn, Bruce, Cabell, Christopher H., Naik, Snehal U., Klassen, Preston, Panés, Julián

“…Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the…”
Get full text

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study by Vermeire, Séverine, Chiorean, Michael, Panés, Julián, Peyrin-Biroulet, Laurent, Zhang, Jinkun, Sands, Bruce E, Lazin, Krisztina, Klassen, Preston, Naik, Snehal U, Cabell, Christopher H, Sandborn, William J

“…Abstract Background and Aims Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. In a phase 2, randomised, double-blind,…”
Get full text

Peroxisome Proliferator-Activated Receptor-α Activation Promotes Macrophage Reverse Cholesterol Transport Through a Liver X Receptor–Dependent Pathway by Nakaya, Kazuhiro, Tohyama, Junichiro, Naik, Snehal U, Tanigawa, Hiroyuki, MacPhee, Colin, Billheimer, Jeffrey T, Rader, Daniel J

“…OBJECTIVE—Peroxisome proliferator-activated receptor-α (PPARα) activation has been shown in vitro to increase macrophage cholesterol efflux, the initial step…”
Get full text

PPARγ activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI by Toh, Sue-Anne, Millar, John S., Billheimer, Jeffrey, Fuki, Ilia, Naik, Snehal U., Macphee, Colin, Walker, Max, Rader, Daniel J.

“…PPARγ agonists, used in the treatment of Type 2 diabetes, can raise HDL-cholesterol, therefore could potentially stimulate macrophage-to-feces reverse…”
Get full text

Both the Peroxisome Proliferator-Activated Receptor δ Agonist, GW0742, and Ezetimibe Promote Reverse Cholesterol Transport in Mice by Reducing Intestinal Reabsorption of HDL-Derived Cholesterol by Briand, François, Naik, Snehal U., Fuki, Ilia, Millar, John S., Macphee, Colin, Walker, Max, Billheimer, Jeffrey, Rothblat, George, Rader, Daniel J.

“…Peroxisome proliferator‐activated receptor δ (PPARδ) agonism increases HDL cholesterol and has therefore the potential to stimulate macrophage‐to‐feces reverse…”
Get full text

Su1926 FECAL CALPROTECTIN AND C-REACTIVE PROTEIN LEVELS ARE CORRELATED WITH LONG TERM CLINICAL AND ENDOSCOPIC OUTCOMES: ANALYSIS OF THE OASIS OPEN LABEL EXTENSION TRIAL OF ETRASIMOD FOR ULCERATIVE COLITIS by Yarur, Andres J., Chiorean, Michael V., Zhang, Jinkun, Reinisch, Walter, Vermeire, Severine, Panes, Julian, Peyrin-Biroulet, Laurent, Sands, Bruce E., Cabell, Chris, Naik, Snehal U., Sandborn, William J.

Get full text

764 Long-Term Efficacy and Safety of Etrasimod for Ulcerative Colitis: Results From the Open-Label Extension of the OASIS Study by Chiorean, Michael, Vermeire, Séverine, Panés, Julian, Peyrin-Biroulet, Laurent, Zhang, Jinkun, Sands, Bruce E., Lazin, Krisztina, Cabell, Chris H., Naik, Snehal U., Klassen, Preston, Sandborn, William J.

“…INTRODUCTION: Etrasimod, a once-daily, oral, selective, sphingosine-1-phosphate receptor modulator, was previously tested in the 12-week (wk) phase 2,…”
Get full text

PPARα activation promotes macrophage reverse cholesterol transport through an LXR-dependent pathway by Nakaya, Kazuhiro, Tohyama, Junichiro, Naik, Snehal U, Tanigawa, Hiroyuki, Jaye, Michael, MacPhee, Colin, Billheimer, Jeffrey T, Rader, Daniel J

Get full text